Please login to the form below
chemotherapy
This page shows the latest chemotherapy news and features for those working in and with pharma, biotech and healthcare.
J&J’s targeted bladder cancer treatment gets US approval
The drug, which will only be used in those whose disease has progressed during or following prior platinum-containing chemotherapy, received a breakthrough designation from the FDA in September last year,
Latest news
-
Lynparza set for further expansion with EU approval in breast cancer
The OlympiAD trial supported the approval, and showed Lynparza produced an improvement in progression-free survival compared to chemotherapy in patients with germline BRCA-mutated metastatic breast cancer. ... 4.2 months for chemotherapy). Patients
-
Bluebird gets European recommendation for gene therapy Zynteglo
The patient then receives chemotherapy to prepare their bone marrow for the modified HSCs, which are re-administered through an infusion.
-
Keytruda adds another NSCLC approval in Europe
The approval is based on data from KEYNOTE-407, a Phase 3 study evaluating Keytruda in combination with chemotherapy compared with chemotherapy alone. ... It was found that Keytruda plus chemotherapy reduced the risk of death by 36% in those with
-
Tecentriq gains first IO approval in triple negative breast cancer
compared with Abraxane alone in PD-L1-positive patients with unresectable locally advanced or metastatic TNBC who had not received prior chemotherapy for metastatic disease. ... range of chemotherapy regimens, plus Keynote-119, which is a trial of the
-
Tecentriq combo gains European NSCLC approval
In combination with chemotherapy and Roche’s older cancer treatment Avastin, Tecentriq can now treat those with EGFR mutant, or ALK-positive metastatic non-squamous non-small cell lung cancer (NSCLC). ... In addition, those in the Tecentriq combo arm
More from news
Approximately 6 fully matching, plus 776 partially matching documents found.
Latest Intelligence
-
Combining therapies and combining research
Without effective antibiotics, much of the success of modern medicine, such as the levels of unprecedented survival rates from major surgery or super effective, chemotherapy treatment, would be totally compromised.
-
Immuno-oncology in 2019: the rapid evolution continues
In December the FDA approved its use in combination with Avastin and chemotherapy in non-squamous NSCLC patients, based on results from the IMpower150 study. ... Keytruda monotherapy showed significant improvement in overall survival compared with
-
Drug launches to watch in 2019
be treated with intensive chemotherapy. ... are ineligible for intensive chemotherapy, to go along with its existing indications in chronic lymphocytic leukaemia (CLL).
-
Is China ready for a pharmaceutical gold rush?
Earlier this year, data showed Keytruda combined with chemotherapy could cut the risk of death among previously untreated lung cancer patients by 51%.
-
AstraZeneca’s oncology renaissance
that has not spread widely around the body after platinum chemotherapy or radiotherapy. ... However, recent overall survival results from the MYSTIC trial, which studied Imfinzi with CTLA4 inhibitor tremelimumab, have just confirmed the combination
More from intelligence
Approximately 0 fully matching, plus 25 partially matching documents found.
Latest appointments
-
Dr Sotirios Stergiopoulos leaves Shire for Ipsen
affairs strategies and a strong expertise in oncology drug development that includes chemotherapy, immunology drugs and targeted agents across various tumour indications.
-
BMS appoints oncology development head
Dr Namouni first joined Bristol-Myers Squibb in France in 1999 as a life-cycle manager for chemotherapy drug Taxol (paclitaxel) and has since held a number of increasingly senior positions
-
AP Pharma overhauls senior management team
AP Pharma's lead product APF530 for the prevention of chemotherapy-induced nausea and vomiting.
-
AP Pharma appoints Dendreon’s Jesse Hollingsworth to lead sales
Joins as company prepares to advance APF350 to treat side effects of chemotherapy. ... The appointment comes as AP Pharma prepares to advance its lead product APF350, which is intended for the prevention of acute- and delayed-onset chemotherapy-induced
-
Bayer’s former oncology head Robert Rosen joins AP Pharma
Will lead launch of drug to prevent chemotherapy-induced nausea. AP Pharma has appointed the former global head of oncology at Bayer Healthcare Robert Rosen as its new senior VP and ... In this role he will lead efforts at the US-based specialty pharma
More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest from PMHub
-
Innovation in pharma: the highs and lows of the current healthcare economy
Also in cancers: chimeric antigen receptor T cell (CAR-T) therapy, a type of cancer immunology that could dismiss chemotherapy in some cancers, is now licensed in the US. .
-
CASE STUDY: Creation of Global Value Dossiers for a US-based Global Pharmaceutical Company
Febrile Neutropenia (FN) during adjuvant chemotherapy is associated with significant morbidity, mortality risk, and incremental costs. ... The client wanted a vendor to develop content for a Global Value Dossier (GVD) about the burden of febrile
-
How pembrolizumab will change the management of advanced lung cancer
The Phase III KEYNOTE-024 trial assessed pembrolizumab compared to standard of care (SOC) platinum-based chemotherapies in patients with previously untreated stage IV, programmed cell death ligand 1 (PD-L1)
-
Products as portfolios: positioning immuno-oncology products
These changes, in turn, are having a fundamental impact on approaches to treatment and standards of care in the same way that surgery, radiotherapy, and chemotherapy have done in the past.
-
Immunotherapy in oncology
This is very different to how we currently assess chemotherapies – by their response rates – where stable disease would be perceived as a poor response.
More from PMHub
Approximately 0 fully matching, plus 8 partially matching documents found.
Featured jobs
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
- Project Manager - Medical Communications – South Wales
-
Excellent Remuneration Package
- Experienced / Senior Account Director - Publications - London
-
Up to £80, 000 plus great benefits
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Senior Account Manager- Pharma and Life Scienes
-
Competitive salary and benefits
- Senior / Principal Medical Writer - MedComms - Home Based / Vari...
-
Excellent Remuneration Packages
- Account Manager / Senior Account Manager - Healthcare Advertisin...
-
Excellent Remuneration
- Account Director – London based Medical Communications Agency
-
Excellent Remuneration Package
-
Director – Healthcare PR
-
Salary TBC
-
Senior Medical Writer
-
Salary TBC
- Freelance Medical Writer - Healthcare Advertising - London
-
Employment Type:. Type of Job:. Region:. Salary:. 250 to 330 per day
-
Senior Medical Writer
-
Competitive salary and benefits
- Project Manager - Digital Healthcare - London
-
Excellent Remuneration Package
- Senior Account Director/ Associate Director- Pharma and Life Sci...
-
Competitive salary and benefits
-
Account Director, Medical Education
-
Salary TBC
- Editor – Medical Education Agency – Bucks
-
Salary TBC
Subscribe to our email news alerts
- With Spiriva under pressure, Boehringer moves to bolster pipeline
- Genfit claims FDA breakthrough status for liver disease drug
- Mereo’s shareholders back OncoMed takeover
- Lucid Group announces the appointment of new CFO
- From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
- Q&A: Niels Lund
PMHub
Anthill Agency
Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...
Latest intelligence
- From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
- How pharma is progressing their commitment in patient engagement...
- Cuttsy+Cuttsy awarded CPD Platinum by the IPA
- Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
- Breaking Bad
- Six behaviours separate the good brand teams from the bad...
Quick links
Infographics
